MTOR and breast cancer: Mutations of the p110α catalytic domain of PI3K, encoded by the PIK3CA gene, are the most common genetic alterations of the PI3K/Akt/mammalian target of rapamycin (mTOR) pathway in BC, being identified in approximately 20% of all BCs.